Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|November 16, 2015
Medication Management in Inflammatory Bowel Disease
Author(s)Davy James, Managing Editor
Marc O'Connor, chief operating officer of Curant Health, discusses counseling patients on a therapeutic regimen for IBD.
Advertisement
Marc O'Connor, chief operating officer of Curant Health, discusses counseling patients on a therapeutic regimen for IBD.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
5